FYI... Oncosil remains on schedule for EU Commercialisation EU...

FYI...
Oncosil remains on schedule for EU Commercialisation

EU Commercialisation of OncoSilTM remains on schedule

for approval in Q4, 2015

• Following the recent granted ISO certification for OncoSilTM, filing

remains on schedule for Conformité Européene (CE) Marking

approval in Q4, 2015

• Commercialisation in the EU would also facilitate sales in other

major markets ex-US

Significant billion dollar market and growing unmet

medical need

• The World Cancer Research Fund estimated that in 2012,

338,000 people globally were diagnosed with pancreatic cancer1

• Estimated total market opportunity for OncoSilTM in pancreatic

cancer exceeds US$1bn

• Primary liver cancer is the 6th most common cancer in the world,

with 782,000 new cases diagnosed in 20122,3

• Value of the primary liver cancer market is expected to exceed

US$1.4bn